Genome sequencing and gene expression analyses of prostate tumours have highlighted
the potential importance of genetic and epigenetic changes observed in WNT signalling …

Purpose: We identify which nonantibiotic strategies could reduce the risk of infectious
complications following prostate biopsy. Materials and Methods: We performed a literature …

Background Darolutamide is a potent androgen-receptor inhibitor that has been associated
with increased overall survival among patients with nonmetastatic, castration-resistant …

Purpose: Current standard imaging techniques are insufficient to reliably detect lymph node
metastases in prostate cancer. Recently ligands of PSMA (prostate specific membrane …

Background Prostate cancer is commonly diagnosed in men worldwide. Surgery, in the form
of radical prostatectomy, is one of the main forms of treatment for men with localised prostate …

Background Vascular-targeted photodynamic therapy, a novel tissue-preserving treatment
for low-risk prostate cancer, has shown favourable safety and efficacy results in single-arm …

Context Current evidence-based management for clinically localised prostate cancer
includes active surveillance, surgery, external beam radiotherapy (EBRT) and …

Background Clinical prognostic grou**s for localised prostate cancers are imprecise, with
30–50% of patients recurring after image-guided radiotherapy or radical prostatectomy. We …

Background Understanding the heterogeneous genotypes and phenotypes of prostate
cancer is fundamental to improving the way we treat this disease. As yet, there are no …

177Lu-prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) using
inhibitors of PSMA is a novel therapeutic option in patients with metastatic castration …